



## **'Resistance is futile?' – paradoxical inhibitory effects of K<sub>ATP</sub> channel closure in glucagon-secreting $\alpha$ -cells**

Zhang, Q., Dou, H., & Rorsman, P. (2020). 'Resistance is futile?' – paradoxical inhibitory effects of K<sub>ATP</sub> channel closure in glucagon-secreting  $\alpha$ -cells. *Journal of Physiology*, 598(21), 4765-4780.  
<https://doi.org/10.1113/JP279775>

[Link to publication record in Ulster University Research Portal](#)

**Published in:**  
Journal of Physiology

**Publication Status:**  
Published (in print/issue): 30/10/2020

**DOI:**  
[10.1113/JP279775](https://doi.org/10.1113/JP279775)

**Document Version**  
Publisher's PDF, also known as Version of record

**General rights**  
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**  
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [pure-support@ulster.ac.uk](mailto:pure-support@ulster.ac.uk).

## TOPICAL REVIEW


# 'Resistance is futile?' – paradoxical inhibitory effects of $K_{ATP}$ channel closure in glucagon-secreting $\alpha$ -cells

Quan Zhang<sup>1</sup> , Haiqiang Dou<sup>2</sup> and Patrik Rorsman<sup>1,2</sup> 

<sup>1</sup>Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK


<sup>2</sup>Metabolic Physiology Unit, Institute of Neuroscience and Physiology, University of Göteborg, PO Box 430, Göteborg, SE-405 30, Sweden

Edited by: Ian Forsythe & Ruth Murrell-Lagnado



**Abstract** By secreting insulin and glucagon, the  $\beta$ - and  $\alpha$ -cells of the pancreatic islets play a central role in the regulation of systemic metabolism. Both cells are equipped with ATP-regulated

**Quan Zhang** obtained his BSc at Shandong University and his PhD at the University of Lund. He currently holds a university research lectureship at the University of Oxford (funded by an RD Lawrence Fellowship from Diabetes UK). **Haiqiang Dou** obtained his BSc and PhD at Peking University. He currently holds a tenured research position at the University of Gothenburg in Sweden. **Patrik Rorsman** is Professor of Diabetic Medicine at the University of Oxford and a Distinguished Investigator at the University of Gothenburg.



potassium ( $K_{ATP}$ ) channels that are regulated by the intracellular ATP/ADP ratio. In  $\beta$ -cells,  $K_{ATP}$  channels are active at low (non-insulin-releasing) glucose concentrations. An increase in glucose leads to  $K_{ATP}$  channel closure, membrane depolarization and electrical activity that culminates in elevation of  $[Ca^{2+}]_i$  and initiation of exocytosis of the insulin-containing secretory granules. The  $\alpha$ -cells are also equipped with  $K_{ATP}$  channels but they are under strong tonic inhibition at low glucose, explaining why  $\alpha$ -cells are electrically active under hypoglycaemic conditions and generate large  $Na^+$ - and  $Ca^{2+}$ -dependent action potentials. Closure of residual  $K_{ATP}$  channel activity leads to membrane depolarization and an increase in action potential firing but this stimulation of electrical activity is associated with inhibition rather than acceleration of glucagon secretion. This paradox arises because membrane depolarization reduces the amplitude of the action potentials by voltage-dependent inactivation of the  $Na^+$  channels involved in action potential generation. Exocytosis in  $\alpha$ -cells is tightly linked to the opening of voltage-gated P/Q-type  $Ca^{2+}$  channels, the activation of which is steeply voltage-dependent. Accordingly, the inhibitory effect of the reduced action potential amplitude exceeds the stimulatory effect resulting from the increased action potential frequency. These observations highlight a previously unrecognised role of the action potential amplitude as a key regulator of pancreatic islet hormone secretion.

(Received 25 April 2020; accepted after revision 24 July 2020; first published online 27 July 2020)

**Corresponding author** Professor P. Rorsman: Headington, Oxford, Oxfordshire OX3 7LE, United Kingdom.

Email: patrik.rorsman@drl.ox.ac.uk

**Abstract figure legend** The confocal images of a mouse pancreatic islet with  $\beta$ -cells in red (top left),  $\alpha$ -cells in green (middle left) and merged image (bottom left). The images were taken at the top of an islet using an upright confocal microscope, which is why a clear separation of the  $\beta$ - and  $\alpha$ -cells is not as evident as in the centre of the islet. Panels to the right show the effects of  $K_{ATP}$  channel closure on electrical activity in  $\beta$ - (top right) and  $\alpha$ -cells (middle right). The schematic (lower right) summarizes the relationship between  $K_{ATP}$  channel closure/electrical activity on insulin and glucagon secretion. A decrease in  $K_{ATP}$  channel activity leads to a biphasic stimulation of insulin secretion (from a low basal value) but inhibition of glucagon secretion (from a high basal rate) despite similar effects on electrical activity in  $\alpha$ - and  $\beta$ -cells. This Topical Review discusses this paradox.

## Introduction

In most cells, potassium ( $K^+$ ) channel activity constitutes the principal background membrane conductance, which explains why the resting membrane potential usually approximates the  $K^+$  equilibrium potential ( $E_K$ ;  $\sim -70$  mV). In general, an increase in  $K^+$  channel activity lowers electrical excitability by clamping the membrane potential at  $E_K$  and reducing the input resistance; both factors making it more difficult for the cell to generate action potentials. Conversely, a decrease in  $K^+$  channel activity increases electrical excitability by producing membrane depolarization and increasing the membrane resistance. Under the latter conditions, the opening of individual  $Na^+$  or  $Ca^{2+}$  channels may suffice for the cell to depolarize to the threshold for action potential firing (Fenwick *et al.* 1982).

ATP-sensitive potassium ( $K_{ATP}$ ) channels are expressed in a number of cells including cardiomyocytes, skeletal muscle, smooth muscle cells and certain neurones (Huang *et al.* 2019). However, their role is particularly evident in the  $\beta$ -cells of the pancreatic islets (Ashcroft, 2007). The pancreatic islets represent the endocrine part of the

pancreas and make up about 1% of its mass, corresponding to  $\sim 1$  g in humans (Rorsman & Ashcroft, 2018). The islets are micro-organs consisting of (on average)  $\sim 200$  endocrine cells: insulin-producing  $\beta$ -cells (75% of islet cells) and glucagon-producing  $\alpha$ -cells (15–20%). In addition, there are a small number (5%) of somatostatin-releasing  $\delta$ -cells. Insulin and glucagon are the body's principal glucose-regulating hormones (Frayn & Evans, 2019). They are released in response to increases (hyperglycaemia) and decreases (hypoglycaemia) in plasma glucose concentrations, respectively. Collectively they ensure that plasma glucose is maintained at  $\sim 5$  mM in humans.

In  $\beta$ -cells, an increase in plasma glucose (for example, following ingestion of a carbohydrate-rich meal) stimulates insulin secretion by closing  $K_{ATP}$  channels (Rorsman & Ashcroft, 2018). Intriguingly,  $K_{ATP}$  channels are also found in the glucagon-secreting  $\alpha$ -cells (Bokvist *et al.* 1999). Given the reciprocal regulation of insulin and glucagon secretion by glucose, the question arises as to how  $K_{ATP}$  channel closure *stimulates* secretion in  $\beta$ -cells but *inhibits* it in  $\alpha$ -cells. In this Topical Review we consider this conundrum.

## K<sub>ATP</sub> channels

K<sub>ATP</sub> channels are octameric heterocomplexes of four KIR6.2 (encoded by *Kcnj11*) and four SUR1 (encoded by *Abcc8*) subunits (Seino, 1999). They are regulated by variations of the intracellular ATP concentrations: they are active in the absence of ATP and are inhibited by increasing concentrations of ATP with an IC<sub>50</sub> of  $\sim 10 \mu\text{M}$  in both  $\alpha$ - and  $\beta$ -cells (Cook & Hales, 1984; Bokvist *et al.* 1999). K<sub>ATP</sub> channels closed by ATP can be reactivated by Mg-ADP (Dunne & Petersen, 1986; Kakei *et al.* 1986) and in the intact cell the channel activity is therefore believed to be regulated by the submembrane ATP/ADP ratio.

The K<sub>ATP</sub> channel is the molecular target of the hypoglycaemic sulphonylureas (SUs) (Trube *et al.* 1986), compounds that have been used to treat type-2 diabetes (T2D) since the early 1950s. Tolbutamide is an example of the first generation SUs and blocks the K<sub>ATP</sub> channels with an IC<sub>50</sub> of  $7 \mu\text{M}$ ; second generation SUs (like glibenclamide) inhibit channel activity at nanomolar concentrations. Conversely, the K<sub>ATP</sub> channels are activated by K<sup>+</sup> channel openers such as diazoxide, which activates the channel with an EC<sub>50</sub> of  $20\text{--}30 \mu\text{M}$  in  $\beta$ - and  $\alpha$ -cells (Zunkler *et al.* 1988; Zhang *et al.* 2013).

Because of its central role in the control of systemic metabolism, the  $\beta$ -cell can be regarded as the archetypal metabolically regulated cell. We will therefore start by summarizing the role of the K<sub>ATP</sub> channel in insulin secretion. We will then consider the more controversial role of K<sub>ATP</sub> channels in the glucagon-secreting  $\alpha$ -cell against the backdrop of the  $\beta$ -cell. There are several excellent reviews on the structure and function of the K<sub>ATP</sub> channels and the respective roles of the two subunits in its regulation (Seino, 1999; Nichols, 2006; McTaggart *et al.* 2010). These aspects will therefore not be reviewed here.

## K<sub>ATP</sub> channels in metabolic sensing: the $\beta$ -cell

$\beta$ -cell electrical activity is tightly correlated with insulin secretion (Rorsman & Ashcroft, 2018). At low (1 mM) glucose (when insulin secretion is suppressed), the  $\beta$ -cell is hyperpolarised ( $-70 \text{ mV}$ ) and electrically silent. Increasing glucose to concentrations  $\geq 6 \text{ mM}$  (i.e. close to the normal plasma glucose levels) induces membrane depolarization. When the membrane potential reaches a threshold of  $\sim -50 \text{ mV}$ , the  $\beta$ -cells start generating oscillatory electrical activity consisting of bursts of action potentials that originate from depolarized plateaux separated by electrically silent repolarized intervals. The bursts of action potentials leads to increases in  $[\text{Ca}^{2+}]_i$  that trigger exocytosis of the insulin-containing secretory granules by mechanisms similar to those involved in neurotransmitter release (Fig. 1A and C) (Rorsman

& Ashcroft, 2018). As in neurones, exocytosis of the insulin-containing granules appears to be determined by the local  $[\text{Ca}^{2+}]_i$  in close proximity to the inner mouth of the  $\text{Ca}^{2+}$  channels (Pertusa *et al.* 1999; Barg *et al.* 2001).

In  $\beta$ -cells, the glucose-induced membrane depolarization and associated initiation of action potential firing are mediated by changes in K<sub>ATP</sub> channel activity. Under hypoglycaemic conditions, K<sub>ATP</sub> channel activity is high because of a low cytoplasmic ATP/ADP ratio and the combination of a negative membrane potential and low membrane resistance prevents electrical activity. When plasma glucose rises, accelerated glucose uptake into the  $\beta$ -cells and the associated stimulation of metabolism increase the cytoplasmic ATP/ADP ratio and thereby causes K<sub>ATP</sub> channel closure.

When K<sub>ATP</sub> channel activity is reduced, the  $\beta$ -cells depolarize because the residual K<sup>+</sup> permeability is no longer sufficient to counteract the depolarizing influence of other membrane conductances that were previously too small to affect the membrane potential. The identity of the depolarizing background membrane conductance remains to be unequivocally identified; candidates include TRPM2 or Piezo1 (Yosida *et al.* 2014; Deivasikamani *et al.* 2019) and/or Cl<sup>−</sup>-permeable LRRC8 channels (also known as SWELL1 or VRAC) (Stuhlmann *et al.* 2018).

As reviewed previously (Rorsman & Ashcroft, 2018),  $\beta$ -cell electrical activity reflects the activation of voltage-gated  $\text{Ca}^{2+}$  and K<sup>+</sup> channels, which underlie the up- and downstroke of the action potential, respectively. In mouse  $\beta$ -cells, the  $\text{Ca}^{2+}$  channels are L- and R-type whereas in human  $\beta$ -cells, L- and P/Q-type  $\text{Ca}^{2+}$  channels predominate. Voltage-gated Na<sup>+</sup> channels also contribute but mainly at glucose concentrations just above the threshold for insulin secretion (Braun *et al.* 2008). However, in mouse  $\beta$ -cells the Na<sup>+</sup> channels exhibit an unusual voltage dependence of inactivation and in most cells they are completely inactivated at the normal resting potential of  $-70 \text{ mV}$  (Zhang *et al.* 2014; Godazgar *et al.* 2018).

The repolarization of the action potential results from the opening of Kv2.1 (mouse) or Kv2.2 (human) and large-conductance  $\text{Ca}^{2+}$ -activated K<sup>+</sup> channels (Jacobson *et al.* 2007; Braun *et al.* 2008; Houamed *et al.* 2010). Pharmacological inhibition of the voltage-gated K<sup>+</sup> channels amplifies glucose-induced insulin secretion by increasing the duration and amplitude of the action potentials (Rorsman *et al.* 2011).

The oscillatory electrical activity seen at the intermediate glucose concentration and its conversion into uninterrupted action potential reflects the complex cross-talk between  $\text{Ca}^{2+}$  entry, intracellular  $\text{Ca}^{2+}$  ATPase activity and  $\text{Ca}^{2+}$ -induced (via changes in the ATP/ADP ratio) of K<sub>ATP</sub> channel activity (Kanno *et al.* 2002).


Like glucose, SUs promptly and reversibly depolarize the  $\beta$ -cell and initiate action potential firing in  $\beta$ -cells (Fig. 1B), which accounts for their insulin-releasing capacity. When applied at intermediate glucose concentrations (10 mM), they also convert oscillatory electrical activity into continuous action potential firing (Henquin, 1988; Kanno *et al.* 2002), in keeping with the idea that electrical activity transiently reactivates  $K_{ATP}$  channels until the intracellular ATP/ADP ratio has been restored (Tarasov *et al.* 2012). Conversely, addition of the  $K_{ATP}$  channel activator diazoxide suppresses glucose-induced electrical activity in  $\beta$ -cells (Henquin & Meissner, 1982). Two important conclusions can be drawn from these observations: First,  $K_{ATP}$  channel closure is involved in both the initiation and modulation of  $\beta$ -cell electrical activity. Second, there must be sufficient depolarizing background in  $\beta$ -cells even at low glucose to account for the rapid initiation of electrical activity upon addition of SUs.

Following its release into the bloodstream, secreted insulin acts on the target organs (chiefly the liver) where

it promotes glucose storage until normal blood glucose is restored. When this has occurred, insulin secretion stops by the reversal of the process described above. Thus, insulin secretion is under feedback control via changes in plasma glucose (Fig. 1C).

### Variations on the $K_{ATP}$ channel theme: the $\alpha$ -cell

As mentioned above, the glucagon-producing  $\alpha$ -cells are also equipped with  $K_{ATP}$  channels. At the molecular level, they are identical to those in  $\beta$ -cells and they are similarly influenced by ATP and ADP (Bokvist *et al.* 1999). Unlike  $\beta$ -cells,  $\alpha$ -cells are electrically active at low (1 mM), or even the complete absence of, glucose (Gopel *et al.* 2000). A role for the  $K_{ATP}$  channels in  $\alpha$ -cells may seem counter-intuitive given that glucose reciprocally regulates insulin and glucagon secretion. However, studies in  $K_{ATP}$  channel knockout mice firmly establish their role in glucagon secretion. In islets from such mice, glucagon secretion is strongly inhibited at low glucose, and high glucose and



**Figure 1.  $K_{ATP}$  channels in  $\beta$ -cells**

A, electrical activity in  $\beta$ -cells evoked by an increase in plasma glucose from 1 to 10 mM. B, as in A but tolbutamide (0.2 mM) applied instead of glucose. C, schematic of consensus model of glucose-induced insulin secretion in  $\beta$ -cells. Glut1/2, glucose transporters 1 and 2 (human and mouse, respectively);  $K_{ATP}$  channels, ATP-sensitive  $K^+$  channels;  $\Psi$ , membrane potential; SG, secretory granules. The + and - signs denote stimulation and inhibition, respectively, whereas the arrows ( $\uparrow$ ,  $\downarrow$ ) indicate an increase or decrease of the indicated parameter. The red arrow indicates feedback regulation of insulin secretion via changes in plasma glucose due to (for example) hepatic glucose disposition.



tolbutamide have (unlike what is seen in control islets) little or no further glucagonostatic effect (Gromada *et al.* 2004; Munoz *et al.* 2005; Shiota *et al.* 2005; MacDonald *et al.* 2007; Cheng-Xue *et al.* 2013). We acknowledge that glucagon secretion may also be under paracrine regulation by insulin (Unger & Orci, 2010) or somatostatin (Hauge-Evans *et al.* 2009). Indeed, it is possible that the small inhibition that persists in K<sub>ATP</sub> channel-deficient islets (10% of that in control islets) (Cheng-Xue *et al.* 2013) reflects such paracrine actions. However, whilst somatostatin may contribute to the glucagonostatic effect at high glucose concentrations that are associated with stimulation of somatostatin secretion, its role at low glucose (when somatostatin release is low) must be limited (Zhang *et al.* 2007; Briant *et al.* 2017; Lai *et al.* 2018; Kellard *et al.* 2020). Here we will therefore focus on the alternative possibility that the glucagonostatic actions of glucose and tolbutamide reflect direct effects within the  $\alpha$ -cell itself and that they are mediated by inhibition of K<sub>ATP</sub> channels.

### K<sub>ATP</sub> channels in $\alpha$ -cells vs. $\beta$ -cells: quantitative aspects

Glucagon secretion is traditionally measured in isolated intact pancreatic islets. Many of the earlier studies that suggest little role for the K<sub>ATP</sub> channels in  $\alpha$ -cells were conducted on isolated cells maintained in tissue culture (Barg *et al.* 2000; Quoix *et al.* 2009), which may not be fully representative of the situation *in vivo*. When K<sub>ATP</sub> channel activity is instead measured in  $\alpha$ -cells in acutely isolated intact islets, the resting membrane conductance was found to be 270 pS at 1 mM glucose and reduced to  $\sim$ 200 pS after application of tolbutamide or increasing glucose to 6 mM (the concentration producing maximal inhibition of glucagon secretion) (Zhang *et al.* 2013). The corresponding values in  $\beta$ -cells are 4 nS and 1 nS (Gopel *et al.* 1999). Thus, the net whole-cell K<sub>ATP</sub> conductance in  $\alpha$ -cells is only 70 pS at 1 mM glucose ( $\sim$ 2% of the 3 nS in  $\beta$ -cells). It is likely that most of the residual K<sub>ATP</sub>-independent (tolbutamide-resistant) membrane conductance largely reflects 'leak' across the lipid membrane itself and around the recording electrode as it is not affected by any experimental manipulation and the giga-seal typically has a resistance of 5–10 G $\Omega$  (i.e. 100–200 pS) (Hamill *et al.* 1981).

### Strong tonic inhibition of K<sub>ATP</sub> channels in $\alpha$ -cells at low glucose

The low resting conductance of  $\alpha$ -cells explains why they are electrically active at low glucose. Importantly, it is not simply a consequence of a low expression of the K<sub>ATP</sub> channel in  $\alpha$ -cells. The K<sub>ATP</sub> channel density can be estimated from the increase in K<sup>+</sup> conductance following

the wash-out of intracellular ATP. Such experiments reveal that the K<sub>ATP</sub> channel density (normalised to membrane area) is, if anything, considerably higher in  $\alpha$ -than in  $\beta$ -cells (Bokvist *et al.* 1999), in agreement with gene expression data (DiGruccio *et al.* 2016). This suggests that the K<sub>ATP</sub> channels must be under strong tonic inhibition even in  $\alpha$ -cells exposed to low glucose. Exactly how this occurs remains to be elucidated but it may reflect effective metabolism of fatty acids in  $\alpha$ -cells under hypoglycaemic conditions (Briant *et al.* 2018). Carnitine palmitoyltransferase 1 (CPT1) is a mitochondrial transmembrane enzyme responsible for the formation of acyl-carnitine from long-chain acyl-coenzyme A. This enzyme is considered rate-limiting for  $\beta$ -oxidation of long-chain fatty acids. In mice that lack CPT1 in the  $\alpha$ -cells, glucagon secretion at 1 mM glucose is reduced by 40%. Thus, there is a redundancy of ATP-producing mechanisms in  $\alpha$ -cells. It is therefore of interest that  $\alpha$ -cells (unlike  $\beta$ - and  $\delta$ -cells) also express the low-K<sub>m</sub> hexokinase-1 (*Hk1*) in addition to glucokinase (*Gck*; a high-K<sub>m</sub> hexokinase). Genetic ablation of glucokinase in  $\alpha$ -cells has no effect on  $\alpha$ -cell electrical activity and glucagon secretion at low (1 mM) glucose but abolishes the glucagonostatic effect of high (6 and 20 mM) glucose (Basco *et al.* 2018). However, the impact of genetically ablating hexokinase-1 in  $\alpha$ -cells has not yet been investigated.

Although  $\alpha$ -cell K<sub>ATP</sub> channel activity in the absence of glucose is very low, it is greater than zero; the observed net membrane conductance of 70 pS is equivalent to an average of five K<sub>ATP</sub> channels being active in the entire cell, suggesting that the open probability of the  $\alpha$ -cell's  $>1000$  K<sub>ATP</sub> channels (Bokvist *et al.* 1999) is  $<0.5\%$ . However, even a K<sub>ATP</sub> channel activity as low as this is sufficient to keep the  $\alpha$ -cell membrane potential partially repolarized ( $\sim$ 55 mV) as witnessed by the 10–15 mV depolarization observed when the channels are inhibited by tolbutamide (Fig. 2A) or high glucose (Zhang *et al.* 2013; Babinsky *et al.* 2017). As in  $\beta$ -cells, this depolarization increases action potential firing in  $\alpha$ -cells but this is associated with a suppression rather than stimulation of glucagon secretion. Below we discuss how this paradox arises.


### Functional consequences of K<sub>ATP</sub> channel closure: role of voltage-gated Na<sup>+</sup> and Ca<sup>2+</sup> channels

Glucagon secretion in  $\alpha$ -cells is the product of action potential frequency and the amount of glucagon secreted for each action potential. Normally, each action potential evokes glucagon granule exocytosis, albeit with a probability as low as 0.004 granules/action potential (Fig. 2B). Following the application of tolbutamide, the release probability is reduced by 80% (to 0.0008

granules/action potential) and although there is a 150% increase in action potential frequency, the combination of these effects produces a net 50% decrease in glucagon secretion (Zhang *et al.* 2013).

Why is the release probability reduced? The action potentials in  $\alpha$ -cells reflect the activation of voltage-gated  $\text{Na}^+$  channels and P/Q-type  $\text{Ca}^{2+}$  channels.  $\text{Na}^+$  channels (including those in  $\alpha$ -cells) (Zhang *et al.* 2014) have a dual dependence on membrane potential: depolarization

both activates and inactivates the channels. Unlike what is observed in  $\beta$ -cells where most (if not all)  $\text{Na}^+$  channels are locked in the inactivated state,  $\text{Na}^+$  channels in  $\alpha$ -cells exist in an 'activatable' state (Zhang *et al.* 2014). The  $\alpha$ -cells express Nav1.3  $\text{Na}^+$  channels whereas Nav1.7 predominates in  $\beta$ -cells but this difference is only part of the reason why the  $\text{Na}^+$  currents in the  $\alpha$ -cells inactivate at 50 mV more depolarized membrane potentials than in  $\beta$ -cells (midpoint of inactivation -50 mV rather than



**Figure 2.  $\text{K}_{\text{ATP}}$  channels in  $\alpha$ -cells**

**A**, effects of tolbutamide ( $200 \mu\text{M}$ ) on action potential firing in an  $\alpha$ -cell within a mouse islet exposed to 1 mM glucose. Note that the  $\alpha$ -cell is electrically active and that tolbutamide leads to membrane depolarization and increases action potential firing. **B**, schematic of  $\alpha$ -cell action potentials at 1 mM glucose in the absence and presence of tolbutamide; membrane potential ( $V$ ) shown in top trace (black) and membrane currents flowing through voltage-gated  $\text{Na}^+$  channels ( $I_{\text{Na}}$ ; blue) and P/Q-type  $\text{Ca}^{2+}$  channels ( $I_{\text{Ca(P/Q)}}$ ; red) are indicated. The table (inset, right) summarizes the action potential (AP) frequency (freq.; taken from Zhang *et al.* (2013)), release probability (prob.) and fractional glucagon release (% of content/h; estimated from reported glucagon secretion rates and islet glucagon contents (Knudsen *et al.* 2019)) and converted to number of granules released based on each  $\alpha$ -cell containing 7000 granules (Barg *et al.* 2000). **C**, schematic of effects of glucose and tolbutamide on electrical activity and glucagon secretion in  $\alpha$ -cells at low glucose (left) and at high glucose or in the presence of a high dose of SU (right). At low glucose,  $\text{K}_{\text{ATP}}$  channel activity is low but  $>0$  and this keeps the membrane potential ( $\Psi$ ) of the  $\alpha$ -cell sufficiently depolarized to allow AP firing whilst preventing voltage-dependent inactivation of the voltage-gated  $\text{Na}^+$  channels ( $\text{Na(V)}$ ). The large-amplitude action potentials activate the P/Q-type  $\text{Ca}^{2+}$  channels ( $\text{Ca(P/Q)}$ ). The associated increase in  $[\text{Ca}^{2+}]_i$  triggers exocytosis of glucagon-containing secretory granules (SGs). When glucose is elevated, increased glucose uptake via Glut1 or 3 and the associated increase in ATP/ADP,  $\text{K}_{\text{ATP}}$  channel activity fall to zeros, resulting in strong membrane depolarization, inactivation of the  $\text{Na(V)}$  channels, reduced AP amplitude, less  $\text{Ca}^{2+}$  entry via  $\text{Ca(P/Q)}$  activation and a fall in  $[\text{Ca}^{2+}]_i$ , culminating in suppression of glucagon secretion. It is also possible that a glucose metabolite directly modulates  $\text{Ca(P/Q)}$  and thereby reduces  $\text{Ca}^{2+}$  entry and glucagon secretion (indicated by '?'). Diazoxide may reverse the glucagonostatic effect of high glucose by activation of  $\text{K}_{\text{ATP}}$  channels (black arrow) when used at an appropriate concentration leading to an increase in channel activity comparable to the decrease produced by glucose. **D**, relationship between whole-cell  $\text{K}_{\text{ATP}}$  channel conductance ( $G$ ) and glucagon secretion. The black arrow indicates changes in  $\text{K}_{\text{ATP}}$  channel activity and the resulting change in glucagon secretion when glucose is increased from 1 to 6 mM (arrow). The red curve was estimated by parallel measurements of glucagon secretion at 6 mM glucose in the presence of increasing concentrations of diazoxide ( $1\text{--}100 \mu\text{M}$ ). Data in panel **D** from Zhang *et al.* (2013) (redrawn).

-100 mV); most of the discrepancy is instead attributable to differences in the Na<sup>+</sup> channels' lipid environment in the  $\alpha$ - and  $\beta$ -cell plasma membranes (Godazgar *et al.* 2018). The central role of Na<sup>+</sup> channels in the glucagon secretion at low glucose is underscored by the strong inhibition of glucagon secretion produced by the Na<sup>+</sup> channel blocker tetrodotoxin (TTX) (Zhang *et al.* 2013, 2014).

Because of Na<sup>+</sup> channel inactivation, the peak voltage of the action potentials declines from +10 mV when the membrane potential is -55 mV (or more negative) to -10 mV when the membrane potential is -45 mV (or more positive). This change in peak voltage is highly significant because exocytosis in  $\alpha$ -cell is steeply voltage-dependent, largely reflecting the voltage dependence of the P/Q-type Ca<sup>2+</sup> channels that mediate the Ca<sup>2+</sup> entry for glucagon secretion at low glucose (Fig. 2B). The change in action potential amplitude produced by application of tolbutamide can be estimated to reduce glucagon exocytosis by 80% (Zhang *et al.* 2013), similar to the estimated reduction of glucagon granules' release probability (see above).

It is implicit from the model that exocytosis of the glucagon granules is regulated by [Ca<sup>2+</sup>]<sub>i</sub> close to the inner mouth of the P/Q-type Ca<sup>2+</sup> channels. This is supported by the findings that exocytosis is resistant to intracellular application of millimolar concentrations of the Ca<sup>2+</sup> chelator EGTA (Zhang *et al.* 2013). It remains an open question whether hyperglycaemia inhibits glucagon secretion exclusively by the same (membrane potential-dependent) mechanism or whether glucose metabolism additionally modulates P/Q-type Ca<sup>2+</sup> channel activity by a more direct inhibitory effect. The latter possibility is suggested by studies on the glucagonostatic effects of the incretin hormone GLP-1 (De Marinis *et al.* 2010). Such a direct modulatory effect of glucose would be consistent with the observation that glucose inhibits glucagon secretion evoked by high K<sup>+</sup> (70 mM) stimulation in human islets (Ramracheya *et al.* 2018) (Fig. 2C), an effect that clearly cannot be accounted for by modulation of action potential height. Whether this also applies to mouse  $\alpha$ -cells and the underlying mechanism have not been elucidated. However, it is clear that the glucose-induced changes in action potential height are sufficient to account for most of the glucagonostatic effect of high glucose but this does not exclude the contribution of additional mechanisms.

### Voltage-gated K<sup>+</sup> channels

Action potential repolarization in  $\alpha$ -cells is mediated by the activation of voltage-gated K<sup>+</sup> currents. Gene expression and electrophysiological data suggest evidence for the presence of Kv2.1/2.2 and Kv11.1/11.2 delayed rectifying and Kv4.1 (mouse) and Kv4.3 (human) A-type K<sup>+</sup> currents. Unlike what is observed in  $\beta$ -cells,

pharmacological inhibition of these channels in  $\alpha$ -cells leads to suppression of glucagon secretion at 1 mM glucose (Gromada *et al.* 2004; Ramracheya *et al.* 2010; Spigelman *et al.* 2010), possibly by resulting in a more depolarized interspike voltage that prevents complete Na<sup>+</sup> channel reactivation between the action potentials (Braun & Rorsman, 2010).

### Bell-shaped relationship between K<sub>ATP</sub> channel activity and glucagon secretion: impact of pharmacological activation of K<sub>ATP</sub> channels

If tolbutamide inhibits glucagon secretion, the K<sub>ATP</sub> channel opener diazoxide should have the opposite effect. Indeed, when tested at low concentrations, diazoxide reverses the glucagonostatic effect of high glucose by reversal of the process shown in Fig. 2C. Notably, the concentration of diazoxide that stimulates glucagon secretion must be carefully titrated and depends on the experimental conditions such as the concentration of bovine serum albumin (commonly included in the extracellular medium in glucagon secretion studies). At high concentrations, the repolarizing effect may become so strong that any stimulatory effect on glucagon secretion due to the increase in action potential height might be cancelled out by the inhibition (partial or complete) of action potential firing. Collectively, these considerations suggest that there is a bell-shaped relationship between K<sub>ATP</sub> channel activity and glucagon secretion (Fig. 2D). This concept may – as we will elaborate below – have important implications for the understanding of the dysregulation of glucagon secretion associated with diabetes.

### Role of [Ca<sup>2+</sup>]<sub>i</sub> in glucagon secretion

As discussed above, changes in K<sub>ATP</sub> channel activity modulate action potential firing in  $\alpha$ -cells. Because electrical activity involves the opening of voltage-gated Ca<sup>2+</sup> channels, electrical activity in  $\alpha$ -cells is associated with oscillations in [Ca<sup>2+</sup>]<sub>i</sub> (Kellard *et al.* 2020). Despite the robust inhibitory effects of high glucose on glucagon secretion this associates with surprisingly subtle effects on [Ca<sup>2+</sup>]<sub>i</sub> (Nadal *et al.* 1999; Quoix *et al.* 2009; Le Marchand & Piston, 2012; Zhang *et al.* 2013; Li *et al.* 2015) and although a glucose-induced reduction of [Ca<sup>2+</sup>]<sub>i</sub> is observed in some cells, it continues to oscillate in other cells (Fig. 3A). A similar variability is observed in the responses to tolbutamide when the compound is tested in intact islets (Fig. 3B) (Quesada *et al.* 1999). This has led to the suggestions that glucagon is regulated distal to the elevation of [Ca<sup>2+</sup>]<sub>i</sub> by a direct effect on exocytosis (Hughes *et al.* 2018). Recently, based on imaging of several hundreds of  $\alpha$ -cells, we were



able to demonstrate that (despite a great cell-to-cell variability) increasing glucose from 1 to 6 mM produced a statistically significant reduction of  $[Ca^{2+}]_i$  manifested as a reduction of both frequency and amplitude of  $[Ca^{2+}]_i$  oscillations (Kellard *et al.* 2020). The effect on the amplitude of the  $[Ca^{2+}]_i$  oscillations resembles that produced by blocking the subset of  $Ca^{2+}$  channels (P/Q-type) linked to glucagon secretion at low glucose (De Marinis *et al.* 2010), in keeping with the idea that the effect of glucose culminates in reduced  $Ca^{2+}$  entry.

In addition to the P/Q-type  $Ca^{2+}$  channels,  $\alpha$ -cells are also equipped with L-type  $Ca^{2+}$  channels. Although these channels contribute to action potential firing in  $\alpha$ -cells, blocking them with isradipine or nifedipine does not affect glucagon secretion at 1 mM glucose (MacDonald *et al.* 2007; De Marinis *et al.* 2010). However, L-type  $Ca^{2+}$  channels play a key role in glucagon secretion evoked by adrenaline (and presumably other agents increasing intracellular cAMP) (De Marinis *et al.* 2010) by promoting intracellular  $Ca^{2+}$  release (Hamilton *et al.* 2018).

Consistent with a bell-shaped relationship between  $K_{ATP}$  channel activity and  $\alpha$ -cell  $[Ca^{2+}]_i$ /glucagon secretion, diazoxide abolished  $[Ca^{2+}]_i$  oscillations at low glucose (Le Marchand & Piston, 2012) but was without consistent inhibitory effect or even increased their frequency at high glucose in some cells (Li *et al.* 2015;

Quesada *et al.* 1999; MacDonald *et al.* 2007), whereas complete inhibition of the  $\beta$ -cells was observed. The latter difference may be related to the fact that diazoxide's capacity to activate the  $K_{ATP}$  channels is diminished by high intracellular ATP concentration (Zunkler *et al.* 1988), a concept that would be consistent with the strong tonic inhibition of  $K_{ATP}$  channels in  $\alpha$ -cells.


### Comparison of secretory responses in $\alpha$ - and $\beta$ -cells

Clearly, the mechanism we propose for glucose- and tolbutamide-induced inhibition of glucagon secretion bears a strong resemblance to that which we outline for biphasic insulin secretion (see Abstract illustration). During sustained glucose or SU stimulation of  $\beta$ -cells, there is a time-dependent reduction in action potential amplitude as well as frequency because of voltage-dependent and  $Ca^{2+}$ -dependent inactivation of  $Ca^{2+}$  and  $Na^{+}$  channels (partial or complete, respectively). As in  $\alpha$ -cells, exocytosis in  $\beta$ -cells is voltage-dependent (Gopel *et al.* 2004) and depends on the local  $Ca^{2+}$  concentration at the release sites (Barg *et al.* 2001). This will reduce the rate of insulin because of two synergistic effects: fewer  $Ca^{2+}$  channels remain to be activated (inactivation) and there is less voltage-dependent activation of these (reduced action potential amplitude). It has been argued that this (in combination with the depletion of a pool of readily releasable secretory granules) contributes to the termination of first phase insulin secretion and that second phase secretion results from the generation of smaller action potentials (Rorsman & Ashcroft, 2018). Importantly, the rate of insulin release during the second phase remains much higher than the very low rate of release under basal conditions prior to the initiation of electrical activity. As discussed below, this is highly significant for an understanding of why glucose differentially regulates insulin and glucagon secretion.

In  $\alpha$ -cells, the application of tolbutamide and high glucose also leads to a reduction of action potential height. As in  $\beta$ -cells, this leads to a decrease in exocytosis. However, because  $\alpha$ -cells (unlike  $\beta$ -cells) are electrically active at low glucose, 'basal' glucagon secretion is high and the reduction of action potential height therefore leads to a net inhibition of glucagon secretion (as discussed above) (see Abstract illustration). In conclusion, time-dependent changes in action potential frequency and amplitude shape the secretory responses in both  $\beta$ - and  $\alpha$ -cells.

### $K_{ATP}$ channels also control glucagon secretion in humans

The model outlined above for the regulation of glucagon secretion is largely based on studies of  $\alpha$ -cells in isolated



**Figure 3.** Effects of glucose and tolbutamide on  $[Ca^{2+}]_i$  in  $\alpha$ -cells

A, effects of application of 0.2 mM tolbutamide in three different  $\alpha$ -cells in intact islets exposed to 1 mM glucose. B, as in A but effects of increasing glucose from 1 to 6 mM. Measurements were made using fluo-3 in A and the lower trace in B. The other measurements were performed in  $\alpha$ -cells expressing the  $Ca^{2+}$  sensor GCaMP3 under the proglucagon promoter.

mouse islets. However, key elements of the model have been confirmed in isolated human pancreatic islets; whereas tolbutamide depolarizes human  $\alpha$ -cells and inhibits glucagon secretion (Ramracheya *et al.* 2010), low concentrations of diazoxide reverse the glucagonostatic effect of high glucose (MacDonald *et al.* 2007). Importantly, there are also clinical data to support the model. In healthy individuals, glucagon secretion increases when plasma glucose is lowered to  $\leq 3.6$  mM (by administration of exogenous insulin; Banarer *et al.* (2002)). Parenthetically, the fact that insulin is commonly used to produce hypoglycaemia and stimulate glucagon secretion militates against the prevailing dogma that insulin is a major glucagonostatic factor (Unger & Orci, 2010). This stimulation is abolished in the presence of tolbutamide, suggesting that counter-regulatory glucagon secretion is mediated by an increase in K<sub>ATP</sub> channel activity. Notably, tolbutamide only affects glucagon secretion at low glucose and it is ineffective under normoglycaemic conditions (Fig. 4A), presumably because the K<sub>ATP</sub> channels are already (nearly) maximally inhibited under the latter condition. Application of tolbutamide leads to stimulation of the insulin secretion rate (estimated from the increase in plasma C-peptide, which reflects endogenous insulin release; exogenous insulin will not contain C-peptide); this effect was strongest under normoglycaemic conditions and in terms of absolute magnitude it was reduced by nearly 50% following induction of hypoglycaemia (Fig. 4B). Although the data were interpreted in terms of intra-islet insulin exerting a glucagonostatic effect (Banarer *et al.* 2002), the


findings that K<sub>ATP</sub> channels are present in human  $\alpha$ -cells and control glucagon secretion rather suggest that it reflects a direct effect of the SU on the  $\alpha$ -cells. In agreement with this idea, the K<sub>ATP</sub> channel activator diazoxide also inhibits glucagon secretion evoked by hypoglycaemia without affecting intra-islet insulin secretion (again estimated from C-peptide measurements) (Fig. 4C–D) (Raju & Cryer, 2005). Diazoxide reduced C-peptide by 50% whilst not affecting glucagon secretion when applied under normoglycaemic conditions. By contrast, when the K<sub>ATP</sub> channel opener was tested after induction of hypoglycaemia there was no effect on endogenous insulin release and yet counter-regulatory glucagon secretion was reduced. The finding that both K<sub>ATP</sub> channel activators and inhibitors inhibit glucagon secretion becomes understandable from the bell-shaped relationship documented *in vitro* (Zhang *et al.* 2013).

### Islet K<sub>ATP</sub> channels and diabetes: pathophysiological and therapeutic implications

There are – broadly speaking – two forms of diabetes: type 1 diabetes (T1D) that has been attributed to the autoimmune destruction of the  $\beta$ -cells (resulting in a dramatically reduced insulin content) (Brissova *et al.* 2018) and type-2 diabetes (T2D) that is caused by insufficient insulin secretion (often but not always combined with insulin resistance) (Ahlqvist *et al.* 2018). In T2D, the capacity of glucose to evoke insulin

**Figure 4. Effects of tolbutamide and diazoxide on glucagon secretion in clinical studies**

A–B, glucagon (A) and insulin secretion rate (B; estimated from the release of C-peptide, a proxy for endogenous insulin secretion) measured in the absence and presence of tolbutamide (1 g/h intravenously) under essentially normo- (4.7 mM) and hypoglycaemic (3 mM) conditions. Hypoglycaemia induced by administering insulin intravenously (1.5 or 6 pmol kg<sup>-1</sup> min<sup>-1</sup>). Data from Banarer *et al.* (2002) (redrawn). C–D, as in A–B but measured in the absence and presence of diazoxide (6 mg kg<sup>-1</sup>, orally). Data from Raju & Cryer (2005) (redrawn).



secretion is selectively reduced whereas the insulinotropic capacity of other secretagogues like GLP-1 and arginine are maintained (Ward *et al.* 1984; Deacon & Holst, 2013). These compounds stimulate insulin secretion by mechanisms that are (partially or wholly) independent of  $K_{ATP}$  channel closure (Shigeto *et al.* 2015). This raises the interesting possibility that the impairment of glucose-induced insulin secretion in T2D is caused by the failure of glucose to inhibit the  $K_{ATP}$  channel (possibly reflecting impaired mitochondrial ATP production) (Del Guerra *et al.* 2005). This would account for the therapeutic capacity of the  $K_{ATP}$  channel-blocking SUs; by closing the  $K_{ATP}$  channel they restore action potential firing and insulin secretion in T2D patients. A problem with the SUs is that they, because of their mode of action (inhibiting the  $K_{ATP}$  channels by a direct/non-metabolic effect), disable the normal feedback control of  $\beta$ -cell electrical activity and insulin secretion. Consequently, insulin secretion remains inappropriately stimulated even after normal plasma glucose has been restored or even fallen below the normal range (see Fig. 4B).

Although it has attracted much less attention, both T1D and T2D are also associated with defective glucagon secretion. The dysregulation is dual: too much glucagon is secreted under hyperglycaemic conditions (when it is not needed) and too little is released in response to hypoglycaemia (when it is needed) (Muller *et al.* 1970). A similar dysregulation is seen in 50% of human islet preparations from donors diagnosed with T2D (Zhang *et al.* 2013): in these preparations glucagon secretion at 1 mM glucose is lower than in islets from non-diabetic donors and increasing glucose stimulates rather than inhibits glucagon release (Fig. 5A). These defects can be recapitulated in islets from non-diabetic donors by exposure to low concentrations of diazoxide (Fig. 5B) or by metabolic poisoning (Zhang *et al.* 2013), suggesting that the glucagon secretion defects in T2D result from an increase in  $K_{ATP}$  channel activity due to metabolic derangement in the  $\alpha$ -cell interfering with ATP production (Knudsen *et al.* 2019). In patients with T1D, glucagon secretion is completely refractory to changes in plasma glucose (Gerich *et al.* 1973). This may be also due to an increase in  $\alpha$ -cell  $K_{ATP}$  channel activity. This would explain the observation that a high dose of the SU glimepiride stimulates glucagon secretion in T1D patients whereas it slightly inhibits the release of the hormone in healthy individuals (Cooperberg & Cryer, 2009) (Fig. 5C). We attribute the weak effect of glimepiride in the healthy controls to the fact that this experiment was performed under normoglycaemic conditions (5 mM).

Based on the bell-shaped relationship between  $K_{ATP}$  channel activity and glucagon secretion, we propose that glucagon secretion is suppressed under hypoglycaemic conditions in diabetic patients because  $K_{ATP}$  channel activity has increased beyond the optimal range (Fig. 5D).

The severity of the metabolic defect will determine the clinical phenotype and range (depending on the increase in  $K_{ATP}$  channel activity) between nearly normal (*i*), high rate of glucagon secretion but no effect of glucose (*ii*), inverted glucose responses (*iii*) and low rate of glucagon secretion with no effect of glucose at all (*iv*) as illustrated schematically in Fig. 5D (inset).

These considerations suggest that it may be possible to pharmacologically restore normal glucose regulation of glucagon secretion using SUs. There is evidence from studies in isolated islets from donors diagnosed with T2D that this works *in vitro* (Zhang *et al.* 2013). It will be interesting to establish whether this is also the case in T1D islets. However, for SUs to be effective in patients with diabetes and impaired glucagon secretion, they must be carefully dosed to reduce  $K_{ATP}$  channel activity into the range where glucagon secretion is maximal; the high concentrations normally used for stimulating insulin secretion will probably inhibit glucagon secretion by producing complete inhibition of the  $K_{ATP}$  channels. In fact, such an effect may contribute to the (unacceptably) high risk of hypoglycaemia associated with SU therapy (Ruan *et al.* 2020), which is one of the reasons these compounds are no longer favoured in T2D therapy (Khunti *et al.* 2018). This is because not only do they stimulate the release of insulin under hypoglycaemic conditions (see above), they also abolish the body's counter-regulatory response.


We point out that the bell-shaped relationship between  $K^+$  channel activity and glucagon secretion is agnostic with regard to the type of  $K^+$  channels involved. We have previously proposed that the resting  $K^+$  conductance in  $\alpha$ -cells may be a mosaic of different  $K^+$  channel activities (Briant *et al.* 2016). In healthy  $\alpha$ -cells,  $K_{ATP}$  channels predominate but the situation might be different after the onset of diabetes (Fig. 5E). Indeed, T2D is associated with hypersecretion of somatostatin at low glucose (Vergari *et al.* 2020). Somatostatin inhibits glucagon secretion by several mechanisms including the activation of G protein-coupled inward-rectifying  $K^+$  channels (GIRK) and a direct effect on exocytosis (Rorsman & Huising, 2018). Interestingly, the somatostatin receptor (SSTR) antagonist CYN154806 restores glucagon secretion at 1 mM glucose in diabetic mice and in some islet preparations from donors with T2D (Vergari *et al.* 2020). In such patients, blocking the  $K_{ATP}$  channel component, low-dose SUs might lower the resting  $K^+$  conductance sufficiently to stimulate secretion at 1 mM glucose but it would not correct the suppression due to inhibition of exocytosis. This would account for the fact that SUs, whilst restoring normal glucose regulation, fail to normalise glucagon secretion at 1 mM glucose to the level seen in islets from healthy mice/organ donors without T2D (Knudsen *et al.* 2019). Conversely, an SSTR antagonist would prevent activation of the GIRK channels and reverse the

effect on exocytosis but not the metabolic defect leading to increased K<sub>ATP</sub> channel activity. Thus, a combination of SSTR antagonists and SUs may be required to fully restore normal metabolic regulation of glucagon secretion in patients with T1D and T2D.

### Yin and Yang of K<sup>+</sup> channel activity

In this Topical Review we show – based on observations in pancreatic  $\alpha$ - and  $\beta$ -cells – that K<sup>+</sup> channel closure has a dual effect on electrical excitability

and hormone/neurotransmitter release. Normally, a reduction of K<sup>+</sup> channel activity increases electrical excitability by producing membrane depolarization and increasing the membrane resistance (as exemplified by the  $\beta$ -cell). However, K<sup>+</sup> channel activity must not be reduced too much; excessive and maintained membrane depolarization may lead to voltage-dependent inactivation of the membrane conductances involved in action potential firing, resulting in a paradoxical decrease in electrical excitability (as exemplified by the  $\alpha$ -cell). Under these conditions, (high membrane) resistance is indeed



**Figure 5. K<sub>ATP</sub> channels and dysregulation of glucagon secretion in diabetes**

A, relative change in glucagon secretion measured in islets from healthy donors ( $n = 40$ ) and donors diagnosed with T2D ( $n = 10$ ) in response to an elevation of glucose from 1 to 20 mM. Responses in T2D islets fell into two groups; one with normal regulation ( $n = 5$ ) and one with inverted regulation ( $n = 5$ ). B, glucagon secretion in islets from two healthy organ donors at 1 and 6 mM glucose in the absence and presence of 2  $\mu$ M diazoxide. C, net change of plasma glucagon measured in healthy individuals and in patients with T1D 4 h after administration of the SU glimepiride (4 mg, orally). Data from Cooperberg & Cryer (2009) (redrawn). D, relationship between total whole-cell K channel conductance (G) and glucagon secretion (continuous curve) in T2D patients with normal K<sub>ATP</sub> channel regulation (i) and with small (ii), moderate (iii) or large (iv) increases in K<sub>ATP</sub> channel activity. The arrows indicate the changes in glucagon secretion produced by an elevation of glucose from 1 to 6 mM. The bar graphs (Inset) show the predicted effects of increasing glucose with variable degrees of basal K<sub>ATP</sub> channel hyperactivity. E, schematic illustrating the effects of SU or an SSTR antagonist. The  $\alpha$ -cell is initially repolarized (top trace) because resting whole-cell K<sup>+</sup> conductance in excess of background ( $\Delta$ G) is increased from the optimal 0.1 nS to 0.2 nS (see Fig. 2). This increase may result from either an increase in K<sub>ATP</sub> (grey; due to a metabolic defect in the  $\alpha$ -cells) and/or GIRK (red; due to increased somatostatin release from  $\delta$ -cells) channel activity. Inhibition of K<sub>ATP</sub> channels with SU (middle) or GIRK channels with an SSTR antagonist reduces  $\Delta$ G to the 0.1 nS, which is optimal for  $\alpha$ -cell electrical activity and glucagon secretion.



futile. Thus, there is a yin and yang of  $K^+$  channel activity and electrical excitability. Although our argument here focuses on the role of  $K_{ATP}$  channels and the pancreatic islet  $\alpha$ - and  $\beta$ -cells, the concept might be equally applicable to other types of  $K^+$  channel and other cell types/tissues. For example, in the brain's supra-chiasmatic nucleus, closure of small conductance  $Ca^{2+}$ -activated  $K^+$ -channels causes membrane depolarization and yet suppresses action potential firing (Belle *et al.* 2009). Our data suggest that the glucagon-secreting  $\alpha$ -cells are regulated similarly and do not obey conventional electrophysiological expectations.

## The way forward

We acknowledge that this Topical Review has a slant towards electrophysiological explanations. However, this does not mean that events beneath the plasma membrane are irrelevant or uninteresting! As we have tried to discuss above, there must be metabolic differences between the  $\beta$ - and  $\alpha$ -cells that ensure that ATP is maintained at sufficiently high levels to keep the  $K_{ATP}$  channels almost fully closed even during protracted hypoglycaemia to ensure continuous release of glucagon but how this occurs is not known. If this mechanism becomes defective in diabetes, it might explain the dysregulation of glucagon secretion associated with the disease and the loss of appropriate counter-regulatory glucagon secretion in some of the patients.

It is currently unknown whether the glucagon secretion defects associated with diabetes develop in  $\alpha$ -cells independently of the disruption of  $\beta$ -cell function or whether they are a consequence of diabetes. Data from mouse models of diabetes suggest that the dysregulation of glucagon secretion is secondary to hyperglycaemia-induced intracellular acidification of the  $\alpha$ -cell that interferes with mitochondrial ATP production that in turn results in  $K_{ATP}$  channel activation and suppression of glucagon secretion (Knudsen *et al.* 2019). It will be important to establish whether this also applies to human  $\alpha$ -cells and whether these defects can be reversed by pharmacological interventions. The finding that low concentrations of SUs partially correct the glucagon secretion in diabetic islets *in vitro* suggests that this is feasible (Zhang *et al.* 2013) but whether these findings can be translated into improved clinical management remains to be established in clinical trials. Importantly, the SUs must be carefully dosed to reduce  $K_{ATP}$  channel activity by  $\sim 50\%$  ( $IC_{50}$ ) as higher concentrations inhibit glucagon secretion (Zhang *et al.* 2013). A stable plasma concentration around the  $IC_{50}$  is difficult to achieve therapeutically with currently available SUs and small changes in the concentration will have large effects on  $K_{ATP}$  channel activity/glucagon secretion. Successful translation into the clinic may therefore require a  $K_{ATP}$  channel blocker

with a mode of action distinct from that of the currently used lipophilic SUs that reach the binding site following solvation in the plasma membrane (Zunkler *et al.* 1989).

Finally, impaired counter-regulatory glucagon secretion with the risk of severe (potentially fatal) hypoglycaemia represents a barrier towards optimal glycaemic control. The only effective treatment available for recurrent life-threatening hypoglycaemia is islet or pancreas transplantation but the need for lifelong immunosuppression makes this a last resort (Harlan, 2016). Importantly, not all patients with diabetes experience severe hypoglycaemia and 80% of patients with T2D and 60% of patients with T1D seem protected even after 5 years of insulin therapy (UK Hypoglycaemia Study Group, 2007). Why hypoglycaemia only affects some patients is not known but it is tempting to speculate that this subgroup is genetically predisposed. Whilst there has been much progress in the understanding of the genetic basis of the insulin secretion defects in T2D (Mahajan *et al.* 2018), hardly anything is known about the genetics of the glucagon secretion defects. With the advent of human iPSC-derived glucose-responsive  $\alpha$ -cells with electrophysiological properties that closely resemble those of primary human  $\alpha$ -cells (Peterson *et al.* 2020), it might be possible to compare glucagon secretion in response to hypoglycaemia and its relationship to electrical activity in  $\alpha$ -cells derived from diabetes patients with good glycaemic control and those with an elevated risk of hypoglycaemia. This represents an exciting – but challenging – area of future research into the dysregulation of glucagon secretion in diabetes.

## References

- Ahlqvist E, Storm P, Karajamaki A, Martinell M, Dorkhan M, Carlsson A, Vikman P, Prasad RB, Aly DM, Almgren P, Wessman Y, Shaat N, Spegel P, Mulder H, Lindholm E, Melander O, Hansson O, Malmqvist U, Lernmark A, Lahti K, Forsen T, Tuomi T, Rosengren AH & Groop L (2018). Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* **6**, 361–369.
- Ashcroft FM (2007). The Walter B. Cannon physiology in perspective lecture, 2007. ATP-sensitive  $K^+$  channels and disease: from molecule to malady. *Am J Physiol Endocrinol Metab* **293**, E880–889.
- Babinsky VN, Hannan FM, Ramracheya RD, Zhang Q, Nesbit MA, Hugill A, Bentley L, Hough TA, Joynson E, Stewart M, Aggarwal A, Prinz-Wohlgenannt M, Gorvin CM, Kallay E, Wells S, Cox RD, Richards D, Rorsman P & Thakker RV (2017). Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy. *Endocrinology* **158**, 2486–2502.
- Banarer S, McGregor VP & Cryer PE (2002). Intra-islet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. *Diabetes* **51**, 958–965.



- Barg S, Galvanovskis J, Gopel SO, Rorsman P & Eliasson L (2000). Tight coupling between electrical activity and exocytosis in mouse glucagon-secreting  $\alpha$ -cells. *Diabetes* **49**, 1500–1510.
- Barg S, Ma X, Eliasson L, Galvanovskis J, Gopel SO, Obermuller S, Platzer J, Renstrom E, Trus M, Atlas D, Striessnig J & Rorsman P (2001). Fast exocytosis with few Ca(2+) channels in insulin-secreting mouse pancreatic B cells. *Biophys J* **81**, 3308–3323.
- Basco D, Zhang Q, Salehi A, Tarasov A, Dolci W, Herrera P, Spiliotis I, Berney X, Tarussio D, Rorsman P & Thorens B (2018).  $\alpha$ -cell glucokinase suppresses glucose-regulated glucagon secretion. *Nat Commun* **9**, 546.
- Belle MD, Diekman CO, Forger DB & Piggins HD (2009). Daily electrical silencing in the mammalian circadian clock. *Science* **326**, 281–284.
- Bokvist K, Olsen HL, Hoy M, Gotfredsen CF, Holmes WF, Buschard K, Rorsman P & Gromada J (1999). Characterisation of sulphonylurea and ATP-regulated K<sup>+</sup> channels in rat pancreatic A-cells. *Pflugers Arch* **438**, 428–436.
- Braun M, Ramracheya R, Bengtsson M, Zhang Q, Karanaukaite J, Partridge C, Johnson PR & Rorsman P (2008). Voltage-gated ion channels in human pancreatic  $\beta$ -cells: electrophysiological characterization and role in insulin secretion. *Diabetes* **57**, 1618–1628.
- Braun M & Rorsman P (2010). The glucagon-producing  $\alpha$  cell: an electrophysiologically exceptional cell. *Diabetologia* **53**, 1827–1830.
- Briant L, Salehi A, Vergari E, Zhang Q & Rorsman P (2016). Glucagon secretion from pancreatic  $\alpha$ -cells. *Ups J Med Sci* **121**, 113–119.
- Briant LJ, Zhang Q, Vergari E, Kellard JA, Rodriguez B, Ashcroft FM & Rorsman P (2017). Functional identification of islet cell types by electrophysiological fingerprinting. *J R Soc Interface* **14**.
- Briant LJB, Dodd MS, Chibalina MV, Rorsman NJG, Johnson PRV, Carmeliet P, Rorsman P & Knudsen JG (2018). CPT1a-dependent long-chain fatty acid oxidation contributes to maintaining glucagon secretion from pancreatic islets. *Cell Rep* **23**, 3300–3311.
- Brissova M, Haliyur R, Saunders D, Shrestha S, Dai C, Blodgett DM, Bottino R, Campbell-Thompson M, Aramandla R, Poffenberger G, Lindner J, Pan FC, von Herrath MG, Greiner DL, Shultz LD, Sanyoura M, Philipson LH, Atkinson M, Harlan DM, Levy SE, Prasad N, Stein R & Powers AC (2018).  $\alpha$  cell function and gene expression are compromised in type 1 diabetes. *Cell Rep* **22**, 2667–2676.
- Cheng-Xue R, Gomez-Ruiz A, Antoine N, Noel LA, Chae HY, Ravier MA, Chimienti F, Schuit FC & Gilon P (2013). Tolbutamide controls glucagon release from mouse islets differently than glucose: involvement of K(ATP) channels from both  $\alpha$ -cells and  $\delta$ -cells. *Diabetes* **62**, 1612–1622.
- Cook DL & Hales CN (1984). Intracellular ATP directly blocks K<sup>+</sup> channels in pancreatic B-cells. *Nature* **311**, 271–273.
- Cooperberg BA & Cryer PE (2009).  $\beta$ -cell-mediated signaling predominates over direct  $\alpha$ -cell signaling in the regulation of glucagon secretion in humans. *Diabetes Care* **32**, 2275–2280.
- De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S, Habib AM, Moritoh Y, Zhang E, Reimann F, Rosengren A, Shibasaki T, Gribble F, Renstrom E, Seino S, Eliasson L & Rorsman P (2010). GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca<sup>2+</sup> channel-dependent exocytosis. *Cell Metab* **11**, 543–553.
- Deacon CF & Holst JJ (2013). Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. *Expert Opin Pharmacother* **14**, 2047–2058.
- Deivasikamani V, Dhayalan S, Abudushalamu Y, Mughal R, Visnagri A, Cuthbertson K, Scragg JL, Munsey TS, Viswambharan H, Muraki K, Foster R, Sivaprasadarao A, Kearney MT, Beech DJ & Sukumar P (2019). Piezo1 channel activation mimics high glucose as a stimulator of insulin release. *Sci Rep* **9**, 16876.
- Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S, Torri S, Pollera M, Boggi U, Mosca F, Del Prato S & Marchetti P (2005). Functional and molecular defects of pancreatic islets in human type 2 diabetes. *Diabetes* **54**, 727–735.
- DiGrucchio MR, Mawla AM, Donaldson CJ, Noguchi GM, Vaughan J, Cowing-Zitron C, van der Meulen T & Huising MO (2016). Comprehensive  $\alpha$ ,  $\beta$  and  $\delta$  cell transcriptomes reveal that ghrelin selectively activates  $\delta$  cells and promotes somatostatin release from pancreatic islets. *Mol Metab* **5**, 449–458.
- Dunne MJ & Petersen OH (1986). Intracellular ADP activates K<sup>+</sup> channels that are inhibited by ATP in an insulin-secreting cell line. *FEBS Lett* **208**, 59–62.
- Fenwick EM, Marty A & Neher E (1982). A patch-clamp study of bovine chromaffin cells and of their sensitivity to acetylcholine. *J Physiol* **331**, 577–597.
- Frayn KN & Evans R (2019). *Human Metabolism: A Regulatory Perspective*. Wiley Blackwell's, Oxford.
- Gerich JE, Langlois M, Noacco C, Karam JH & Forsham PH (1973). Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic  $\alpha$  cell defect. *Science* **182**, 171–173.
- Godazgar M, Zhang Q, Chibalina MV & Rorsman P (2018). Biphasic voltage-dependent inactivation of human NaV 1.3, 1.6 and 1.7 Na(+) channels expressed in rodent insulin-secreting cells. *J Physiol* **596**, 1601–1626.
- Gopel S, Kanno T, Barg S, Galvanovskis J & Rorsman P (1999). Voltage-gated and resting membrane currents recorded from B-cells in intact mouse pancreatic islets. *J Physiol* **521** Pt 3, 717–728.
- Gopel S, Zhang Q, Eliasson L, Ma XS, Galvanovskis J, Kanno T, Salehi A & Rorsman P (2004). Capacitance measurements of exocytosis in mouse pancreatic  $\alpha$ -,  $\beta$ - and  $\delta$ -cells within intact islets of Langerhans. *J Physiol* **556**, 711–726.
- Gopel SO, Kanno T, Barg S & Rorsman P (2000). Patch-clamp characterisation of somatostatin-secreting  $\delta$ -cells in intact mouse pancreatic islets. *J Physiol* **528**, 497–507.
- Gromada J, Ma XS, Hoy M, Bokvist K, Salehi A, Berggren PO & Rorsman P (2004). ATP-sensitive K<sup>+</sup> channel-dependent regulation of glucagon release and electrical activity by glucose in wild-type and SUR1(-/-) mouse  $\alpha$ -cells. *Diabetes* **53**, S181–S189.

- Hamill OP, Marty A, Neher E, Sakmann B & Sigworth FJ (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. *Pflugers Arch* **391**, 85–100.
- Hamilton A, Zhang Q, Salehi A, Willems M, Knudsen JG, Ringgaard AK, Chapman CE, Gonzalez-Alvarez A, Surdo NC, Zaccolo M, Basco D, Johnson PRV, Ramracheya R, Rutter GA, Galione A, Rorsman P & Tarasov AI (2018). Adrenaline Stimulates Glucagon Secretion by Tpc2-Dependent Ca(2+) Mobilization From Acidic Stores in Pancreatic alpha-Cells. *Diabetes* **67**, 1128–1139.
- Harlan DM (2016). Islet Transplantation for Hypoglycemia Unawareness/Severe Hypoglycemia: Caveat Emptor. *Diabetes Care* **39**, 1072–1074.
- Hauge-Evans AC, King AJ, Carmignac D, Richardson CC, Robinson IC, Low MJ, Christie MR, Persaud SJ & Jones PM (2009). Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. *Diabetes* **58**, 403–411.
- Henquin JC (1988). ATP-sensitive K<sup>+</sup> channels may control glucose-induced electrical activity in pancreatic B-cells. *Biochem Biophys Res Commun* **156**, 769–775.
- Henquin JC & Meissner HP (1982). Opposite effects of tolbutamide and diazoxide on 86Rb<sup>+</sup> fluxes and membrane potential in pancreatic B cells. *Biochem Pharmacol* **31**, 1407–1415.
- Houamed KM, Sweet IR & Satin LS (2010). BK channels mediate a novel ionic mechanism that regulates glucose-dependent electrical activity and insulin secretion in mouse pancreatic beta-cells. *J Physiol* **588**, 3511–3523.
- Huang Y, Hu D, Huang C & Nichols CG (2019). Genetic Discovery of ATP-Sensitive K(+) Channels in Cardiovascular Diseases. *Circ Arrhythm Electrophysiol* **12**, e007322.
- Hughes JW, Ustione A, Lavagnino Z & Piston DW (2018). Regulation of islet glucagon secretion: Beyond calcium. *Diabetes Obes Metab* **20** Suppl 2, 127–136.
- Jacobson DA, Kuznetsov A, Lopez JP, Kash S, Ammala CE & Philipson LH (2007). Kv2.1 ablation alters glucose-induced islet electrical activity, enhancing insulin secretion. *Cell Metab* **6**, 229–235.
- Kakei M, Kelly RP, Ashcroft SJ & Ashcroft FM (1986). The ATP-sensitivity of K<sup>+</sup> channels in rat pancreatic B-cells is modulated by ADP. *FEBS Lett* **208**, 63–66.
- Kanno T, Rorsman P & Gopel SO (2002). Glucose-dependent regulation of rhythmic action potential firing in pancreatic beta-cells by K(ATP)-channel modulation. *J Physiol* **545**, 501–507.
- Kellard JA, Rorsman NJG, Hill TG, Armour SL, van der Bunt M, Rorsman P, Knudsen JG & Briant LJB (2020). Reduced somatostatin signalling leads to hypersecretion of glucagon in mice fed a high-fat diet. *Molecular metabolism*, 101021.
- Khunti K, Chatterjee S, Gerstein HC, Zoungas S & Davies MJ (2018). Do sulphonylureas still have a place in clinical practice? *Lancet Diabetes Endocrinol* **6**, 821–832.
- Knudsen JG, Hamilton A, Ramracheya R, Tarasov A, Brereton M, Haythorne e, Chibalina MV, Spegel P, Mulder H, Zhang Q, Ashcroft FM, Adam J & Rorsman P (2019). Dysregulation of glucagon secretion by hyperglycemia-induced sodium-dependent reduction of ATP production. *Cell Metab* **29**, 430–442.e4.
- Lai BK, Chae H, Gomez-Ruiz A, Cheng P, Gallo P, Antoine N, Beauloye C, Jonas JC, Seghers V, Seino S & Gilon P (2018). Somatostatin Is Only Partly Required for the Glucagonostatic Effect of Glucose but Is Necessary for the Glucagonostatic Effect of KATP Channel Blockers. *Diabetes* **67**, 2239–2253.
- Le Marchand SJ & Piston DW (2012). Glucose decouples intracellular Ca2+ activity from glucagon secretion in mouse pancreatic islet alpha-cells. *PLoS One* **7**, e47084.
- Li J, Yu Q, Ahooghalandari P, Gribble FM, Reimann F, Tengholm A & Gylfe E (2015). Submembrane ATP and Ca2+ kinetics in alpha-cells: unexpected signaling for glucagon secretion. *FASEB J* **29**, 3379–3388.
- MacDonald PE, De Marinis YZ, Ramracheya R, Salehi A, Ma X, Johnson PR, Cox R, Eliasson L & Rorsman P (2007). A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. *PLoS Biol* **5**, e143.
- Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, Payne AJ, Steinthorsdottir V, Scott RA, Grarup N, Cook JP, Schmidt EM, Wuttke M, Sarnowski C, Mägi R, Nano J, Gieger C, Trompet S, Lecoeur C, Preuss MH, Prins BP, Guo X, Bielak LF, Below JE, Bowden DW, Chambers JC, Kim YJ, Ng MCY, Petty LE, Sim X, Zhang W, Bennett AJ, Bork-Jensen J, Brummett CM, Canouil M, Eckardt K-U, Fischer K, Kardia SLR, Kronenberg F, Läll K, Liu C-T, Locke AE, Luan JA, Ntalla I, Nylander V, Schönherr S, Schurmann C, Yengo L, Bottinger EP, Brandslund I, Christensen C, Dedoussis G, Florez JC, Ford I, Franco OH, Frayling TM, Giedraitis V, Hackinger S, Hattersley AT, Herder C, Ikram MA, Ingelsson M, Jørgensen ME, Jørgensen T, Kriebel J, Kuusisto J, Ligthart S, Lindgren CM, Linneberg A, Lyssenko V, Mamakou V, Meitinger T, Mohlke KL, Morris AD, Nadkarni G, Pankow JS, Peters A, Sattar N, Stančáková A, Strauch K, Taylor KD, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tuomilehto J, Witte DR, Dupuis J, Peyser PA, Zeggini E, Loos RJJ, Froguel P, Ingelsson E, Lind L, Groop L, Laakso M, Collins FS, Jukema JW, Palmer CNA, Grallert H, Metspalu A, Dehghan A, Köttgen A, Abecasis GR, Meigs JB, Rotter JI, Marchini J, Pedersen O, Hansen T, Langenberg C, Wareham NJ, Stefansson K, Gloyn AL, Morris AP, Boehnke M & McCarthy MI (2018). Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet* **50**, 1505–1513.
- McTaggart JS, Clark RH & Ashcroft FM (2010). The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. *J Physiol* **588**, 3201–3209.
- Muller WA, Faloona GR, Aguilar-Parada E & Unger RH (1970). Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. *N Engl J Med* **283**, 109–115.

- Munoz A, Hu M, Hussain K, Bryan J, Aguilar-Bryan L & Rajan AS (2005). Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement. *Endocrinology* **146**, 5514–5521.
- Nadal A, Quesada I & Soria B (1999). Homologous and heterologous asynchronicity between identified  $\alpha$ -,  $\beta$ - and  $\delta$ -cells within intact islets of Langerhans in the mouse. *J Physiol* **517**(Pt 1), 85–93.
- Nichols CG (2006). K<sub>ATP</sub> channels as molecular sensors of cellular metabolism. *Nature* **440**, 470–476.
- Pertusa JA, Sanchez-Andres JV, Martin F & Soria B (1999). Effects of calcium buffering on glucose-induced insulin release in mouse pancreatic islets: an approximation to the calcium sensor. *J Physiol* **520**(Pt 2), 473–483.
- Peterson QP, Veres A, Chen L, Slama MQ, Kenty JHR, Hassoun S, Brown MR, Dou H, Duffy CD, Zhou Q, Matveyenko AV, Tyrberg B, Sorhede-Winzell M, Rorsman P & Melton DA (2020). A method for the generation of human stem cell-derived  $\alpha$  cells. *Nat Commun* **11**, 2241.
- Quesada I, Nadal A & Soria B (1999). Different effects of tolbutamide and diazoxide in  $\alpha$ ,  $\beta$ -, and  $\delta$ -cells within intact islets of Langerhans. *Diabetes* **48**, 2390–2397.
- Quoix N, Cheng-Xue R, Mattart L, Zeinoun Z, Guiot Y, Beauvois MC, Henquin JC & Gilon P (2009). Glucose and pharmacological modulators of ATP-sensitive K<sup>+</sup> channels control [Ca<sup>2+</sup>]<sub>i</sub> by different mechanisms in isolated mouse  $\alpha$ -cells. *Diabetes* **58**, 412–421.
- Raju B & Cryer PE (2005). Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. *Diabetes* **54**, 757–764.
- Ramracheya R, Chapman C, Chibalina M, Dou H, Miranda C, Gonzalez A, Moritoh Y, Shigeto M, Zhang Q, Braun M, Clark A, Johnson PR, Rorsman P & Briant LJB (2018). GLP-1 suppresses glucagon secretion in human pancreatic  $\alpha$ -cells by inhibition of P/Q-type Ca(2+) channels. *Physiol Rep* **6**, e13852.
- Ramracheya R, Ward C, Shigeto M, Walker JN, Amisten S, Zhang Q, Johnson PR, Rorsman P & Braun M (2010). Membrane potential-dependent inactivation of voltage-gated ion channels in  $\alpha$ -cells inhibits glucagon secretion from human islets. *Diabetes* **59**, 2198–2208.
- Rorsman P & Ashcroft FM (2018). Pancreatic  $\beta$ -cell electrical activity and insulin secretion: of mice and men. *Physiol Rev* **98**, 117–214.
- Rorsman P, Eliasson L, Kanno T, Zhang Q & Gopel S (2011). Electrophysiology of pancreatic  $\beta$ -cells in intact mouse islets of Langerhans. *Prog Biophys Mol Biol* **107**, 224–235.
- Rorsman P & Huising MO (2018). The somatostatin-secreting pancreatic  $\delta$ -cell in health and disease. *Nature Reviews Endocrinology* **14**, 404–414.
- Ruan Y, Moysova Z, Tan GD, Lumb A, Davies J & Rea RD (2020). Inpatient hypoglycaemia: understanding who is at risk. *Diabetologia* **63**, 1299–1304.
- Seino S (1999). ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. *Annu Rev Physiol* **61**, 337–362.
- Shigeto M, Ramracheya R, Tarasov AI, Cha CY, Chibalina MV, Hastoy B, Philippaert K, Reinbothe T, Rorsman N, Salehi A, Sones WR, Vergari E, Weston C, Gorelik J, Katsura M, Nikolaev VO, Vennekens R, Zaccolo M, Galione A, Johnson PR, Kaku K, Ladds G & Rorsman P (2015). GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. *J Clin Invest* **125**, 4714–4728.
- Shiota C, Rocheleau JV, Shiota M, Piston DW & Magnuson MA (2005). Impaired glucagon secretory responses in mice lacking the type 1 sulfonylurea receptor. *Am J Physiol Endocrinol Metab* **289**, E570–577.
- Spigelman AF, Dai X & MacDonald PE (2010). Voltage-dependent K(+) channels are positive regulators of  $\alpha$  cell action potential generation and glucagon secretion in mice and humans. *Diabetologia* **53**, 1917–1926.
- Stuhlmann T, Planells-Cases R & Jentsch TJ (2018). LRRC8/VRAC anion channels enhance  $\beta$ -cell glucose sensing and insulin secretion. *Nat Commun* **9**, 1974.
- Tarasov AI, Semplici F, Ravier MA, Bellomo EA, Pullen TJ, Gilon P, Sekler I, Rizzuto R & Rutter GA (2012). The mitochondrial Ca<sup>2+</sup> uniporter MCU is essential for glucose-induced ATP increases in pancreatic  $\beta$ -cells. *PLoS One* **7**, e39722.
- Trube G, Rorsman P & Ohno-Shosaku T (1986). Opposite effects of tolbutamide and diazoxide on the ATP-dependent K<sup>+</sup> channel in mouse pancreatic  $\beta$ -cells. *Pflugers Arch* **407**, 493–499.
- UK Hypoglycaemia Study Group (2007). Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. *Diabetologia* **50**, 1140–1147.
- Unger RH & Orci L (2010). Paracrinology of islets and the paracrinopathy of diabetes. *Proc Natl Acad Sci U S A* **107**, 16009–16012.
- Ward WK, Bolgiano DC, McKnight B, Halter JB & Porte D, Jr (1984). Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. *J Clin Invest* **74**, 1318–1328.
- Vergari E, Denwood G, Salehi A, Zhang Q, Adam J, Alrifaiy A, Wernstedt Asterholm I, Benrick A, Chibalina MV, Eliasson L, Guida C, Hill TG, Hamilton A, Ramracheya R, Reimann F, Rorsman NJG, Spiliotis I, Tarasov AI, Walker JN, Rorsman P & Briant LJB (2020). Somatostatin secretion by Na(+)-dependent Ca(2+)-induced Ca(2+) release in pancreatic  $\delta$ -cells. *Nature metabolism* **2**, 32–40.
- Yosida M, Dezaki K, Uchida K, Kodera S, Lam NV, Ito K, Rita RS, Yamada H, Shimomura K, Ishikawa SE, Sugawara H, Kawakami M, Tominaga M, Yada T & Kakei M (2014). Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion. *Diabetes* **63**, 3394–3403.
- Zhang Q, Bengtsson M, Partridge C, Salehi A, Braun M, Cox R, Eliasson L, Johnson PR, Renstrom E, Schneider T, Berggren PO, Gopel S, Ashcroft FM & Rorsman P (2007). R-type Ca(2+)-channel-evoked CICR regulates glucose-induced somatostatin secretion. *Nat Cell Biol* **9**, 453–460.

- Zhang Q, Chibalina MV, Bengtsson M, Groschner LN, Ramracheya R, Rorsman NJ, Leiss V, Nassar MA, Welling A, Gribble FM, Reimann F, Hofmann F, Wood JN, Ashcroft FM & Rorsman P (2014). Na<sup>+</sup> current properties in islet alpha- and beta-cells reflect cell-specific Scn3a and Scn9a expression. *J Physiol* **592**, 4677–4696.
- Zhang Q, Ramracheya R, Lahmann C, Tarasov A, Bengtsson M, Braha O, Braun M, Brereton M, Collins S, Galvanovskis J, Gonzalez A, Groschner LN, Rorsman NJ, Salehi A, Travers ME, Walker JN, Gloyn AL, Gribble F, Johnson PR, Reimann F, Ashcroft FM & Rorsman P (2013). Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. *Cell Metab* **18**, 871–882.
- Zunkler BJ, Lenzen S, Manner K, Panten U & Trube G (1988). Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K<sup>+</sup> currents in pancreatic B-cells. *Naunyn Schmiedebergs Arch Pharmacol* **337**, 225–230.
- Zunkler BJ, Trube G & Panten U (1989). How do sulfonylureas approach their receptor in the B-cell plasma membrane? *Naunyn Schmiedebergs Arch Pharmacol* **340**, 328–332.

## Additional information

### Competing interests

The authors declare no competing interests.

### Author contributions

QZ and HD researched the data. PR drafted the manuscript, which was edited and approved by all authors.

### Funding

Supported by Diabetes UK (QZ), the Swedish Research Council (PR) and the Helmsley Trust (PR). Concepts presented in this Topical Review are based on studies supported by the Wellcome Trust.

### Keywords

diabetes, glucagon, insulin, K<sub>ATP</sub> channels, membrane potential